MPT Resource Center

Combining Active Pharmaceutical Ingredients: MPT Development & Regulatory Considerations

Integrating Socio-behavioral & Market Research into MPT R&D: Applying Lessons Learned

MPTs & the IMPT Platform

MPTs & the IMPT Platform May 2021 The MPTs & the IMPT Platform is a PowerPoint presentation created by the IMPT Secretariat at CAMI Health to help our colleagues integrate MPTs into their talks and presentations. Please email IMPT@cami-health.org with any feedback on how you used this information. Download the presentation slide deck CAMI Health […]

TRIO Study Brief: Long-Acting Injections for Women’s HIV Prevention in Sub-Saharan Africa: What End-Users Think

Annual National Reproductive Health Conference

10-13 August 2021 Annual National Reproductive Health Conference San Francisco, CA, USA

Toxicity study considerations for HIV prevention and MPT R&D

Bridging the gap: Advancing multipurpose prevention technologies from the lab into the hands of women

The role of cervicovaginal microbiota on contraceptive and MPT development

MCI’s Lemonade Stand Series: “Multipurpose Prevention Technologies (MPTs) & Male Contraception

23rd International AIDS Conference (AIDS 2020: Virtual)

Towards a roadmap to advance non-hormonal contraceptive multipurpose prevention technologies: Strategic insights from key stakeholders

A novel vaginal pH regulator: results from the phase 3 AMPOWER contraception clinical trial

TRIO MPT Research Brief: Listening to Young Women in Kenya and South Africa to Inform Multipurpose “2-in-1” Products for HIV and Pregnancy Prevention

TRIO General Research Brief: What End-Users Think About HIV Prevention Products and Multipurpose Prevention Technologies (MPT)

Estimating the market size for a dual prevention pill: adding contraception to pre-exposure prophylaxis (PrEP) to increase uptake

BU researcher asks, ‘is it time for another contraception revolution?’

Evofem Biosciences enters into financing agreement for up to $80 million, closes first tranche of strategic investment from PDL BioPharma

Better, safer sex: On the hunt for a condom people will actually like

Preferred product attributes of potential multipurpose prevention technologies for unintended pregnancy and sexually transmitted infections or HIV among U.S. women

Assessing the total market for female condoms in Malawi and Zambia

Exploring the Product Development Environment in ARV prevention and MPTs

How to interest providers and retailers in female condoms

Evofem Biosciences completes phase 2b ‘AMPREVENCE’ trial of Amphora for prevention of chlamydia and gonorrhea in women

“We are not the same”: African women’s view of multipurpose prevention products in the TRIO clinical study

Researchers at Queen’s University Belfast have developed a vaginal ring capable of providing sustained delivery of OB-002 (5P12-RANTES) for HIV prevention

MPTs for Reproductive Health

MPTs for Reproductive Health 2019 click to view Factsheet / Outreach Material In this Factsheet / Outreach Material: Health Risk(s): HIV STI / STD Unintended Pregnancy Product Type(s): MPTs Topic(s): Advocacy MPTs Product Development

Fighting HIV/AIDS

Daré Bioscience completes recruitment in pre-pivotal trial of monthly woman-controlled, hormone-free contraceptive candidate, Ovaprene®

The role of antimicrobial peptides in the prevention of sexually transmitted infection (STI)

Tenofovir gel reduces risk for herpes simplex virus type 2 acquisition

Watch: Now a rap song to promote use of condoms

Pre-exposure prophylaxis 2.0: New drugs and technologies in the pipeline

Acceptability of the woman’s condom in a phase III multicenter open-label study

Contraceptive innovation at Women Deliver – A look at the past, the present, the future

Evofem Biosciences announces last patient enrolled for AMPREVENCE, the phase 2b sexually transmitted infections trial of Amphora

Integrating preexposure prophylaxis delivery in routine family planning clinics: A feasibility programmatic evaluation in Kenya

HIV prevention research & development investments: Investing to end the epidemic.

Why we need a contraception revolution

The “who” informs the “what”: Identifying the target population in Sub-Saharan Africa to design impactful multipurpose prevention technologies

Sexually transmitted infections and HIV in the era of antiretroviral treatment and prevention: the biologic basis for epidemiologic synergy

MPT Investment Case Slide Deck

Contraceptive eligibility for women at high risk of HIV

A qualitative systematic review of women’s experiences using contraceptive vaginal rings: Implications for new technologies

G1-S4 or G2-S16 carbosilane dendrimer in combination with Platycodin D as a promising vaginal microbicide candidate with contraceptive activity

Maximise benefits of female condom, physician counsels women

Engaging study participants in interpreting results: lessons from the TRIO study in Kenya and South Africa

2018 annual report: On her own terms

Expanding choices: A look into the Population Council’s multipurpose prevention technology (MPT) product pipeline

What is on the horizon for HIV prevention?

The promise of MPTs